🇺🇸 Insulin Actrapid in United States
69 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 69
Most-reported reactions
- Drug Interaction — 17 reports (24.64%)
- Gastrointestinal Haemorrhage — 9 reports (13.04%)
- Hypoglycaemia — 7 reports (10.14%)
- Hyperglycaemia — 6 reports (8.7%)
- Blood Glucose Increased — 5 reports (7.25%)
- Bradycardia — 5 reports (7.25%)
- Pleural Effusion — 5 reports (7.25%)
- Pneumonia — 5 reports (7.25%)
- Renal Failure Acute — 5 reports (7.25%)
- Thrombocytopenia — 5 reports (7.25%)
Other Diabetes approved in United States
Frequently asked questions
Is Insulin Actrapid approved in United States?
Insulin Actrapid does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Insulin Actrapid in United States?
University of Nottingham is the originator. The local marketing authorisation holder may differ — check the official source linked above.